Critical Care Medicine
Endocrine disorders of pregnancy: Gestational diabetes mellitus, Diabetic ketoacidosis in pregnancy, Acute adrenal crisis in pregnancy, Cushing's syndrome in pregnancy, Hypothyroidism in pregnancy
Related conditions: Gestational diabetes mellitus
Diabetic ketoacidosis in pregnancy
Acute adrenal crisis in pregnancy
Cushing's syndrome in pregnancy
Hypothyroidism in pregnancy
1. Description of the problem
Altered metabolic homeostasis in pregnancy allows for the natural growth and development of the fetus and placenta.
However, these adaptive metabolic changes add a level of complexity to the diagnosis and management of diseases that are either inherent to pregnancy or complicated by pregnancy.
The endocrine and metabolic alterations during pregnancy primarily affect the hypothalamus, pituitary, and adrenal glands.
Nausea, vomiting, abdominal pain, ileus
Polyuria and polydipsia
Mental status changes
Tachycardia and hyperventilation (Kussmaul respirations)
Acute adrenal insufficiency
Hypotension and hypovolemic shock
Nonspecific symptoms such as nausea, vomiting, diarrhea, fatique, muscle weakness, abdominal pain, lethargy, confusion, and coma
Fatigue and muscle weakness
Mental status changes ranging from irritability and depression to coma
It is important to recognize that there are many physiologic changes that occur in pregnancy, such as mild tachycardia, tachypnea, respiratory alkalosis, fatigue, muscle weakness, and peripheral edema, as well as changes in specific laboratory values, such as decreased hemoglobin and creatinine levels, that potentially may confound the diagnosis of any of the endocrine processes that occur in pregnancy.
2. Emergency Management
Improve circulating blood volume with aggressive fluid resuscitation.
Decrease serum glucose with insulin administration.
Clear serum ketoacids (correcting acidosis) with fluid and insulin therapy.
Treat initiating causes of DKA .
Initiate therapy with 0.1 U/kg bolus, then a continuous infusion of 0.1 U/kg/hr.
Prioritize airway, breathing, and circulation.
Aggressive fluid resuscitation with 5% dextrose solution and normal saline (D5NS)
Correct specific electrolyte abnormalities including hypoglycemia, hyponatremia, hyperkalemia, and hypercalcemia.
1st dose of hydrocortisone at 100 mg intravenously
Administer 4-mg intravenous dose of dexamethasone initially instead of hydrocortisone if the ACTH stimulation test is performed.
Fludrocortisone acetate at 0.1 mg orally
Emergent therapy not usually required
Gradual oral replacement with thyroxine for mild cases
For myxedema coma, immediate intravenous levothyroxine treatment at a dose of 500 to 800 micrograms should be administered.
Concomitant glucocorticoid therapy is also given in myxedema coma because of the possibility of adrenal insufficiency, especially in cases of secondary hypothyroidism.
The normal hypermetabolic state of normal pregnancy makes it difficult to differentiate from patients who present with pathologic endocrine and metabolic disorders.
Electrolytes with low bicarbonate level of <15 mEq/L
Serum glucose level usually > 250 mg/dL, although lower levels have been reported in pregnancy
Serum ketones elevated with ≥1:2 dilution
Arterial blood gas with pH <7.3 and anion gap >12 mEq/L
Elevated base deficit > 4 mEq/L
Ketonemia ≥1:2 dilution
Serum glucose level
Complete blood count
Blood urea nitrogen and creatinine levels
Serum cortisol level
Serum calcium or ionized calcium levels
ACTH Cosyntropin stimulation test
Serum cortisol level
24-hour urinary cortisol test - the most definitive test, with values of greater than 50 micrograms daily suggestive of the diagnosis
Dexamethasone suppression test
CRH (corticotropin-releasing hormone) stimulation test
CT and MRI scans to evaluate for pituitary or adrenal tumors
inferior petrosal sinus catheterization
Thyroid function tests of T4, T3 and TSH serum levels
Thyroid-releasing hormone (TRH) stimulation test
High anion gap metabolic acidosis
Elevated blood glucose levels - every 1 to 2 hours
Elevated serum ketones - every 1 to 2 hours
Acute adrenal insufficiency
Low to low-normal cortisol levels
No increase in the plasma cortisol level with the ACTH stimulation test
Increased serum cortisol level
Increased 24-hour urinary free cortisol level of >50 to 100 micrograms/day
Radiographs of the adrenal and pituitary glands to locate tumors
Dexamethasone suppression test will differentiate between excess ACTH production for pituitary adenomas from those with ectopic ACTH-producing tumors.
Increased TSH levels with low serum levels of T4 and T3 hormones
In secondary hypothyroidism, TSH levels will be normal. A TRH stimulation test should be done in these cases to make the appropriate diagnosis.
4. Specific Treatment
Continue insulin until bicarbonate and anion gap normalize and serum ketones are cleared.
Continue 100 mg IV hydrocortisone until acute signs of adrenal crisis resolve, and then transition to oral prednisone if required.
Continue with oral fludrocortisone at 0.1 to 0.2 mg orally daily if signs of adrenal insufficiency persist.
Treatment will depend on the etiology of the cortoisol excess and may include surgery, radiotherapy, chemotherapy, and/or cortisol-inhibiting medications, such as metyrapone, ketoconazole, or aminoglutethimide.
Thryroxine (T4) dosing should be titrated rapidly to reach and then maintain serum TSH concentrations of <2.5 microunits/mL in the 1st trimester or to 3 microunits/mL in the 2nd or 3rd trimester or to trimester-specific TSH ranges.
5. Disease monitoring, follow-up and disposition
Evaluate serum glucose levels and ketones and electrolytes every 2 to 4 hours initally.
Maintain serum potassium levels at 4 to 5 mEq/L.
Anticipate potassium deficit of 5 to 10 mEq/kg body weight.
Replace potassium with either potassium chloride or potassium phosphate.
Correct 75% of fluid deficit over the 1st 24 hours with a normal saline infusion for initial replacement and then add dextrose to the solution when the glucose level is at 250 mg/dL.
The thyroxine dose needs to be increased by 4 to 6 weeks of gestation and may require a 30% to 50% increase in dosage during the pregnancy. When changes are made in thyroxine dosing, thyroid function tests should be measured within 30 to 40 days.
Women with autoimmune thyroid disease should be closely monitored throughout the pregnancy, especially during the 1st trimester, because of the risk of developing hypothyroidism later in the pregnancy.
Women with subclinical hypothyroidism with normal free T4 levels but increased TSH levels should be treated with T4 therapy during the pregnancy.
Changes in glucose metabolism
Variable glucose and insulin levels are seen in pregnancy depending upon the mother's nutritional state.
Fasting glucose levels can decrease by 10% to 20%.
There is increased insulin secretion but a relative state of insulin resistance is present in pregnancy.
Obese pregnant women with preexisting insulin resistance and women with marginal pancreatic reserve are at risk for developing gestational diabetes.
The compensatory respiratory alkalosis of normal pregnancy
Changes in hypothalamic and pituitary metabolism
Both ACTH and cortisol levels are significantly increased in pregnancy, and Cushing's syndrome can be exacerbated.
Acute adrenal crisis may occur precipitated by the stress of labor and delivery in patients with previously undiagnosed adrenal insufficiency.
Thyroid hormones are increased during pregnancy but free levels are normal. TSH levels are decreased but thyroid hormones increase as a result of increased synthesis of thyroxine-binding globulin. Hypothyroidism may occur if if the pregnant woman does not ingest sufficient dietary iodine (200 micrograms daily).
Transient diabetes insipidus can occur during pregnancy from vasopressin resistance. Plasma osmolality decreases in pregnancy by 5 to 10 mOsm/kg.
Incidence of DKA is approximately 2% to 3% in pregnancy with an associated 10% perinatal mortality rate.
In pregnancy, DKA is precipitated by in 40% of cases cessation of insulin therapy and in 20% of cases from infection; 30% of women presented in DKA with no prior antecedent history of diabetes mellitus.
Beta-mimetic tocolytic agents and corticosteroids during pregnancy can also precipitate DKA in pregnancy.
Acute adrenal crisis
Most cases in pregnancy result from abrupt cessation of chronic corticosteroid therapy for prepartum conditions, particularly at the time of labor and delivery.
Occurs rarely during pregnancy
The frequency of ACTH-independent cases of Cushing's syndrome is as high as 60% in pregnant women, with 48% having adenomas and 10% with carcinomas, compared to lower frequency rates in nonpregnant patients. Less frequent causes are secondary to Cushing's disease or bilateral adrenal hyperplasia.
The most common thyroid disease during pregnancy is hypothyroidism. One percent of pregnant women will present with overt hypothyroidism, 2% to 3% will present with subclinical hypothyroidism, and 10% to 15% will have evidence of autoimmune thyroid disease.
Although rare, myxedema coma may be precipitated by infection during pregnancy coupled with the metabolic-related stresses of pregnancy.
DKA represents an acute emergency to both maternal and fetal well-being. Prompt initiation of treatment will correct the associated maternal and fetal metabolic acidosis, hyperglycemia, ketosis, and volume depletion..
Adrenal crisis represents another true emergency for both the mother and the fetus. Prompt treatment with glucocorticoid and mineralocorticoid therapies will restore homeostasis.
The symptoms of Cushing's disease are exacerbated by pregnancy but usually resolve after pregnancy. Improved outcomes are seen with surgery during pregnancy if pituitary or adrenal tumors are detected.
In addition to the maternal manifestations of overt hypothyroidism during pregnancy, hypothyroidism has been associated with damage to fetal intellectual development. T4 therapy has been shown to improve obstetrical outcome but may increase the risk of long-term sequelae in the offspring.
What's the evidence?
Carroll, MA, Yeomans, ER. "Diabetic ketoacidosis in pregnancy". Crit Care Med. vol. 33. 2005. pp. S347-53.
"American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 30: Gestational Diabetes". Obstet Gynecol. vol. 98. 2001. pp. 525-38.
Kamalakannan, D, Baskar, V, Barton, DM. "Diabetic ketoacidosis in pregnancy". Postgrad Med. vol. 79. 2003. pp. 699-714.
LIndsay, JR, Jonklaas, J, Oldfield, EH. "Cushing's syndrome during pregnancy; personal experience and review of the literature". J Clin Endocrinol Metabol. vol. 90. 2005. pp. 3077.
"The Endocrine Society's Clinical Guidelines. Management of thyroid dysfunction during pregnancy and postpartum". J Clin Endocrinol Metab. vol. 92. 2007. pp. S1-47.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Moving Targets: Off-Label Prescribing of Targeted Therapies
- Conditional 10-Year Breast Cancer Recurrence Rates Decline Regardless of Subtype
- New Algorithm Improves Outcome Prediction for Diffuse Large B-Cell Lymphoma
- Immunotherapy Combo in Head and Neck Cancer Shows Activity in Phase 2 Trial
- Trials, Collaboration Might Help Reduce Survival Disparities Between Community, Academic Cancer Centers
- Nutraceuticals/Supplements and Cancer Prevention: All Hype?
- Encorafenib Plus Binimetinib Offers a New Option for MEK+BRAF Inhibition
- Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD
- POT1 Revealed as a Sarcoma Predisposition Gene
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Registration Trial to Look at HRAS-Directed Tipifarnib in HNSCC
- 1 in 5 Patients Readmitted Within 30 Days of Reconstruction Surgery for Head and Neck Cancer
- Treatment-Related Hyperprogression: Concerns Continue to Mount
- Activation-Induced Cytidine Deaminase Transcripts Linked To More Aggressive CLL
- Next-Generation Sequencing Helped Identify Pathways for Transformation of WM to DLBCL